-$1.17 Earnings Per Share Expected for 2seventy bio, Inc. (NASDAQ:TSVT) This Quarter

Equities research analysts expect 2seventy bio, Inc. (NASDAQ:TSVTGet Rating) to post earnings of ($1.17) per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for 2seventy bio’s earnings, with the lowest EPS estimate coming in at ($1.78) and the highest estimate coming in at ($0.80). The business is expected to issue its next earnings results on Monday, January 1st.

On average, analysts expect that 2seventy bio will report full year earnings of ($5.40) per share for the current fiscal year, with EPS estimates ranging from ($7.01) to ($2.37). For the next financial year, analysts forecast that the business will post earnings of ($4.58) per share, with EPS estimates ranging from ($6.79) to ($1.94). Zacks’ EPS averages are an average based on a survey of research analysts that follow 2seventy bio.

2seventy bio (NASDAQ:TSVTGet Rating) last released its earnings results on Thursday, May 12th. The company reported ($3.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.26) by ($0.94). The company had revenue of $8.43 million during the quarter, compared to analysts’ expectations of $22.66 million. 2seventy bio’s revenue for the quarter was down 29.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($3.73) earnings per share.

Several equities analysts have recently commented on the company. SVB Leerink began coverage on 2seventy bio in a research note on Thursday, February 10th. They issued an “outperform” rating and a $38.00 price target on the stock. Zacks Investment Research upgraded shares of 2seventy bio from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a report on Saturday, March 26th. Finally, The Goldman Sachs Group started coverage on shares of 2seventy bio in a report on Monday, May 2nd. They set a “buy” rating and a $26.00 price objective on the stock. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, 2seventy bio currently has an average rating of “Buy” and a consensus target price of $39.67.

Shares of TSVT stock traded up $0.22 during trading hours on Monday, hitting $12.14. 5,937 shares of the company’s stock were exchanged, compared to its average volume of 446,443. 2seventy bio has a fifty-two week low of $10.57 and a fifty-two week high of $64.00. The business’s 50 day moving average price is $15.19.

A number of hedge funds have recently added to or reduced their stakes in TSVT. Metropolitan Life Insurance Co NY acquired a new position in 2seventy bio during the 1st quarter valued at about $25,000. Ameritas Investment Partners Inc. acquired a new position in shares of 2seventy bio in the first quarter worth $30,000. Group One Trading L.P. purchased a new stake in shares of 2seventy bio during the 1st quarter worth about $69,000. GSA Capital Partners LLP bought a new stake in 2seventy bio in the first quarter worth $183,000. Finally, Fiduciary Trust Co. bought a new position in shares of 2seventy bio in the 1st quarter valued at approximately $188,000. Hedge funds and other institutional investors own 50.43% of the company’s stock.

2seventy bio Company Profile (Get Rating)

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma.

Read More

Get a free copy of the Zacks research report on 2seventy bio (TSVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for 2seventy bio (NASDAQ:TSVT)

Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter.